GSK PLC
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Ms E Walmsley
| |||
b)
|
Position/status
|
Chief Executive Officer
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price |
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr R Connor
| |||
b)
|
Position/status
|
President, Global Vaccines
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Ms D Conrad
| |||
b)
|
Position/status
|
SVP, Human Resources
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr J Ford
| |||
b)
|
Position/status
|
SVP and General Counsel
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr N Hirons
| |||
b)
|
Position/status
|
SVP, Global Ethics and Compliance
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Ms S Jackson
| |||
b)
|
Position/status
|
SVP, Global Communications and CEO Office
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr D Jackson
| |||
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
10 (partnership shares)
| ||||
£13.6195
|
10 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
20 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr D Redfern
| |||
b)
|
Position/status
|
Chief Strategy Officer
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr R Simard
| |||
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr P Thomson
| |||
b)
|
Position/status
|
President, Global Affairs
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Ms D Waterhouse
| |||
b)
|
Position/status
|
Chief Executive Officer of ViiV Healthcare
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
10 (partnership shares)
| ||||
£13.6195
|
10 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
20 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Ms V Whyte
| |||
b)
|
Position/status
|
Company Secretary
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.6195
|
9 (partnership shares)
| ||||
£13.6195
|
9 (matching shares)
| ||||
d)
|
Aggregated information
| ||||
Aggregated volume
Price
|
18 Ordinary Shares
£13.6195
| ||||
e)
|
Date of the transaction
|
2021-06-09
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
Attachments
- Original document
- Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 11 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 June 2021 18:22:00 UTC.
